AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Usio, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Prestige Consumer Healthcare (PBH) â€� Form 4: Director John E. Byom was granted 2,094 restricted stock units (RSUs) on 08/05/2025 under the company’s director compensation plan. The grant equals $155,000, calculated from the $74.04 closing price. RSUs vest in one year and convert to one common share each upon the earliest of the director’s death, separation, or a change in control.

No shares were sold; the transaction is coded “A� (acquisition) at $0 cost, confirming it is a non-open-market award. Byom’s direct ownership increases to 54,594 PBH shares.

The filing reflects routine board compensation, adds marginal equity alignment, and has negligible dilution or valuation impact for investors.

Prestige Consumer Healthcare (PBH) � Modulo 4: Il direttore John E. Byom ha ricevuto 2.094 unità azionarie vincolate (RSU) il 05/08/2025 nell’ambito del piano di compensazione per i direttori della società. Il valore dell’assegnazione è di 155.000 $, calcolato sul prezzo di chiusura di 74,04 $. Le RSU maturano in un anno e si convertono in un’azione ordinaria ciascuna al verificarsi del primo evento tra la morte del direttore, la separazione o un cambio di controllo.

Non sono state vendute azioni; la transazione è codificata come “A� (acquisizione) a costo 0 $, confermando che si tratta di un premio non negoziato sul mercato aperto. La proprietà diretta di Byom aumenta a 54.594 azioni PBH.

La comunicazione riflette una normale compensazione del consiglio, aggiunge un lieve allineamento azionario e ha un impatto trascurabile su diluizione e valutazione per gli investitori.

Prestige Consumer Healthcare (PBH) � Formulario 4: El director John E. Byom recibió 2.094 unidades restringidas de acciones (RSU) el 05/08/2025 bajo el plan de compensación para directores de la empresa. La concesión equivale a 155.000 $, calculado con el precio de cierre de 74,04 $. Las RSU se consolidan en un año y se convierten en una acción común cada una ante el primero de los siguientes eventos: fallecimiento del director, separación o cambio de control.

No se vendieron acciones; la transacción está codificada como “A� (adquisición) a un costo de 0 $, confirmando que es una concesión fuera del mercado abierto. La propiedad directa de Byom aumenta a 54.594 acciones PBH.

La presentación refleja una compensación rutinaria del consejo, añade una alineación marginal de capital y tiene un impacto insignificante en la dilución o valoración para los inversores.

Prestige Consumer Healthcare (PBH) â€� Form 4: ì´ì‚¬íš� ì´ì‚¬ John E. Byomì€ 2025ë…� 8ì›� 5ì� 회사ì� ì´ì‚¬ ë³´ìƒ ê³„íšì—� ë”°ë¼ 2,094ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 부여받았습니다. ë¶€ì—� 가치는 종가 74.04달러ë¥� 기준으로 155,000달러ì—� 해당합니ë‹�. RSUëŠ� 1ë…� í›„ì— ì™„ì „íž� ì·¨ë“ë˜ë©°, ì´ì‚¬ì� 사ë§, 퇴임 ë˜ëŠ” ê²½ì˜ê¶� ë³€ê²� ì¤� ê°€ìž� ì´ë¥¸ 시ì ì—� ê°ê° 보통ì£� 1주로 전환ë©ë‹ˆë‹�.

ì£¼ì‹ ë§¤ë„ëŠ� 없었으며, 거래ëŠ� 0달러 비용ì� “Aâ€�(ì·¨ë“) 코드ë¡� 기ë¡ë˜ì–´ 공개 시장ì—서ì� 거래가 아님ì� 확ì¸í•©ë‹ˆë‹�. Byomì� ì§ì ‘ 소유 주ì‹ì€ 54,594ì£� PBHë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

ì� ë³´ê³ ëŠ� ì¼ìƒì ì¸ ì´ì‚¬íš� ë³´ìƒì� ë°˜ì˜í•˜ë©°, 소액ì� ì£¼ì‹ ì •ë ¬ì� 추가하고 투ìžìžì— 대í•� í¬ì„ì´ë‚˜ ê°€ì¹� í‰ê°€ ì˜í–¥ì€ ê±°ì˜ ì—†ìŠµë‹ˆë‹¤.

Prestige Consumer Healthcare (PBH) � Formulaire 4 : Le directeur John E. Byom a reçu 2 094 unités d’actions restreintes (RSU) le 05/08/2025 dans le cadre du plan de rémunération des administrateurs de la société. La subvention équivaut à 155 000 $, calculée sur le cours de clôture de 74,04 $. Les RSU acquièrent leurs droits en un an et se convertissent chacune en une action ordinaire au premier des événements suivants : décès du directeur, départ ou changement de contrôle.

Aucune action n’a été vendue ; la transaction est codée « A » (acquisition) à coût nul, confirmant qu’il s’agit d’une attribution hors marché. La détention directe de Byom passe à 54 594 actions PBH.

Le dépôt reflète une rémunération habituelle du conseil, ajoute un alignement marginal des capitaux propres et a un impact négligeable en termes de dilution ou d’évaluation pour les investisseurs.

Prestige Consumer Healthcare (PBH) � Formular 4: Direktor John E. Byom erhielt am 05.08.2025 2.094 Restricted Stock Units (RSUs) im Rahmen des Vergütungsplans für Direktoren des Unternehmens. Die Zuteilung entspricht 155.000 $, berechnet auf Basis des Schlusskurses von 74,04 $. Die RSUs werden nach einem Jahr fällig und wandeln sich jeweils bei Tod des Direktors, Ausscheiden oder Kontrollwechsel in eine Stammaktie um.

Es wurden keine Aktien verkauft; die Transaktion ist als „A� (Erwerb) mit 0 $ Kosten codiert, was bestätigt, dass es sich um eine nicht am offenen Markt erfolgte Zuteilung handelt. Byoms Direktbesitz erhöht sich auf 54.594 PBH-Aktien.

Die Meldung spiegelt eine routinemäßige Vorstandsvergütung wider, fügt eine marginale Beteiligungsausrichtung hinzu und hat für Investoren kaum Auswirkungen auf Verwässerung oder Bewertung.

Positive
  • Director acquired 2,094 RSUs, increasing equity alignment with shareholders
Negative
  • None.

Insights

TL;DR: Routine RSU grant; minimal dilution; neutral valuation impact; slightly tighter director-shareholder alignment.

The 2,094-unit RSU grant, worth $155k, is standard annual compensation. No cash outlay or open-market purchase occurred, so liquidity and market sentiment remain unchanged. Post-grant ownership of 54,594 shares modestly increases insider exposure but is immaterial relative to PBH’s total float. Because the award vests in 12 months and settles only upon separation or other triggers, near-term share count effects are negligible. Overall, the filing is operationally neutral and should not influence valuation or trading dynamics.

Prestige Consumer Healthcare (PBH) � Modulo 4: Il direttore John E. Byom ha ricevuto 2.094 unità azionarie vincolate (RSU) il 05/08/2025 nell’ambito del piano di compensazione per i direttori della società. Il valore dell’assegnazione è di 155.000 $, calcolato sul prezzo di chiusura di 74,04 $. Le RSU maturano in un anno e si convertono in un’azione ordinaria ciascuna al verificarsi del primo evento tra la morte del direttore, la separazione o un cambio di controllo.

Non sono state vendute azioni; la transazione è codificata come “A� (acquisizione) a costo 0 $, confermando che si tratta di un premio non negoziato sul mercato aperto. La proprietà diretta di Byom aumenta a 54.594 azioni PBH.

La comunicazione riflette una normale compensazione del consiglio, aggiunge un lieve allineamento azionario e ha un impatto trascurabile su diluizione e valutazione per gli investitori.

Prestige Consumer Healthcare (PBH) � Formulario 4: El director John E. Byom recibió 2.094 unidades restringidas de acciones (RSU) el 05/08/2025 bajo el plan de compensación para directores de la empresa. La concesión equivale a 155.000 $, calculado con el precio de cierre de 74,04 $. Las RSU se consolidan en un año y se convierten en una acción común cada una ante el primero de los siguientes eventos: fallecimiento del director, separación o cambio de control.

No se vendieron acciones; la transacción está codificada como “A� (adquisición) a un costo de 0 $, confirmando que es una concesión fuera del mercado abierto. La propiedad directa de Byom aumenta a 54.594 acciones PBH.

La presentación refleja una compensación rutinaria del consejo, añade una alineación marginal de capital y tiene un impacto insignificante en la dilución o valoración para los inversores.

Prestige Consumer Healthcare (PBH) â€� Form 4: ì´ì‚¬íš� ì´ì‚¬ John E. Byomì€ 2025ë…� 8ì›� 5ì� 회사ì� ì´ì‚¬ ë³´ìƒ ê³„íšì—� ë”°ë¼ 2,094ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSU)ë¥� 부여받았습니다. ë¶€ì—� 가치는 종가 74.04달러ë¥� 기준으로 155,000달러ì—� 해당합니ë‹�. RSUëŠ� 1ë…� í›„ì— ì™„ì „íž� ì·¨ë“ë˜ë©°, ì´ì‚¬ì� 사ë§, 퇴임 ë˜ëŠ” ê²½ì˜ê¶� ë³€ê²� ì¤� ê°€ìž� ì´ë¥¸ 시ì ì—� ê°ê° 보통ì£� 1주로 전환ë©ë‹ˆë‹�.

ì£¼ì‹ ë§¤ë„ëŠ� 없었으며, 거래ëŠ� 0달러 비용ì� “Aâ€�(ì·¨ë“) 코드ë¡� 기ë¡ë˜ì–´ 공개 시장ì—서ì� 거래가 아님ì� 확ì¸í•©ë‹ˆë‹�. Byomì� ì§ì ‘ 소유 주ì‹ì€ 54,594ì£� PBHë¡� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

ì� ë³´ê³ ëŠ� ì¼ìƒì ì¸ ì´ì‚¬íš� ë³´ìƒì� ë°˜ì˜í•˜ë©°, 소액ì� ì£¼ì‹ ì •ë ¬ì� 추가하고 투ìžìžì— 대í•� í¬ì„ì´ë‚˜ ê°€ì¹� í‰ê°€ ì˜í–¥ì€ ê±°ì˜ ì—†ìŠµë‹ˆë‹¤.

Prestige Consumer Healthcare (PBH) � Formulaire 4 : Le directeur John E. Byom a reçu 2 094 unités d’actions restreintes (RSU) le 05/08/2025 dans le cadre du plan de rémunération des administrateurs de la société. La subvention équivaut à 155 000 $, calculée sur le cours de clôture de 74,04 $. Les RSU acquièrent leurs droits en un an et se convertissent chacune en une action ordinaire au premier des événements suivants : décès du directeur, départ ou changement de contrôle.

Aucune action n’a été vendue ; la transaction est codée « A » (acquisition) à coût nul, confirmant qu’il s’agit d’une attribution hors marché. La détention directe de Byom passe à 54 594 actions PBH.

Le dépôt reflète une rémunération habituelle du conseil, ajoute un alignement marginal des capitaux propres et a un impact négligeable en termes de dilution ou d’évaluation pour les investisseurs.

Prestige Consumer Healthcare (PBH) � Formular 4: Direktor John E. Byom erhielt am 05.08.2025 2.094 Restricted Stock Units (RSUs) im Rahmen des Vergütungsplans für Direktoren des Unternehmens. Die Zuteilung entspricht 155.000 $, berechnet auf Basis des Schlusskurses von 74,04 $. Die RSUs werden nach einem Jahr fällig und wandeln sich jeweils bei Tod des Direktors, Ausscheiden oder Kontrollwechsel in eine Stammaktie um.

Es wurden keine Aktien verkauft; die Transaktion ist als „A� (Erwerb) mit 0 $ Kosten codiert, was bestätigt, dass es sich um eine nicht am offenen Markt erfolgte Zuteilung handelt. Byoms Direktbesitz erhöht sich auf 54.594 PBH-Aktien.

Die Meldung spiegelt eine routinemäßige Vorstandsvergütung wider, fügt eine marginale Beteiligungsausrichtung hinzu und hat für Investoren kaum Auswirkungen auf Verwässerung oder Bewertung.

false 0001088034 0001088034 2025-08-06 2025-08-06
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 6, 2025
 
USIO, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
000-30152
 
98-0190072
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)
 
3611 Paesanos Parkway, Suite 300, San Antonio, TX
 
78231
(Address of principal executive offices)
 
(Zip Code)
 
(210) 249-4100
(Registrant’s telephone number, including area code)
 
Not applicable.
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common stock, par value $0.001 per share
USIO
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 2.02        Results of Operations and Financial Condition.
 
On August 6, 2025, Usio, Inc. issued a press release announcing financial results for its quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1. The information furnished in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section.
 
This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to its future activities or future events or conditions. These forward-looking statements are identified by the use of words such as “believe,” “expect,” “project,” “anticipate,” “target,” and “launch,” or similar expressions including statements about commercial operations, technology progress, growth and future financial performance of the Company. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that the Company’s security applications may be insufficient; the Company’s ability to adapt to rapid technological change; adverse effects on the Company’s relationships with Automated Clearing House, bank sponsors and credit card associations; the Company’s ability to comply with federal or state regulations; the Company’s exposure to credit risks, data breaches, fraud or software failures, the uncertainty caused by the pandemic and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024. One or more of these factors have affected, and in the future could affect, the Company’s businesses and financial results and could cause actual results to differ materially from plans and projections. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date as of which such statement was made.
 
 
Item 9.01        Financial Statements and Exhibits.
 
99.1
Press Release issued by Usio, Inc., dated August [  ], 2025. (filed herewith)
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Usio, Inc.
 
(Registrant)
   
Date: August 6, 2025
/s/ Louis A. Hoch
 
Name: Louis A. Hoch
 
Title: Chief Executive Officer
 
 

FAQ

What insider transaction did PBH report on Form 4?

Director John E. Byom received 2,094 restricted stock units valued at $155,000 on 08/05/2025.

How many Prestige Consumer Healthcare shares does John E. Byom now own?

After the grant, the director directly owns 54,594 common shares of PBH.

When do the newly granted PBH RSUs vest?

The RSUs vest on the first anniversary of the 08/05/2025 grant date.

Was the PBH insider transaction an open-market purchase?

No. The Form 4 lists the code “A� at $0 cost, indicating a compensatory grant, not a market buy.

Did the filing disclose any share sales by the director?

No share sales were reported; the filing shows only an acquisition of RSUs.
Usio Inc

NASDAQ:USIO

USIO Rankings

USIO Latest News

USIO Latest SEC Filings

USIO Stock Data

50.24M
21.70M
18.14%
25.41%
0.16%
Software - Infrastructure
Functions Related to Depository Banking, Nec
United States
SAN ANTONIO